Clinical Trial News and Research

RSS

Patient on artificial heart receives heart and kidney transplant

Charles Okeke, the Phoenix husband and father of three, made headlines in May 2010 when he became the first patient in the U.S. to be discharged from a hospital with an artificial heart. With the latest technology, the "Freedom Driver," the man without a heart was able to resume his family life and to be free of the confines of a hospital room.

16 Feb 2011

UT Southwestern treats breast-cancer patient with Accuray CyberKnife System

Breast-cancer patient Kristin Wiginton is the first to be treated at UT Southwestern Medical Center with high-beam radiation using the Accuray CyberKnife System, which offers improved cosmetic results, less radiation exposure to surrounding tissue and a shorter treatment period.

16 Feb 2011

CTI's fourth quarter net loss increases to $34.1 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2010.

16 Feb 2011

AMT 2010 total net income increases to EUR 1.4 million

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the year to December 31, 2010.

16 Feb 2011

Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL

Halozyme Therapeutics, Inc. and Roche today announced the first patient received subcutaneous MabThera (rituximab), an anticancer biologic, in a Phase 3 registration trial using Enhanze technology.

16 Feb 2011

Endosense announces completion of enrollment in EFFICAS I clinical study

Endosense, a Swiss medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the EFFICAS I clinical study.

16 Feb 2011

Researchers identify cell of origin for sarcoma

Researchers at Oregon Health & Science University Doernbecher Children's Hospital have defined the cell of origin for a kind of cancer called sarcoma. In a study published today as the Featured Article in the journal Cancer Cell, they report that childhood and adult sarcomas are linked in their biology, mutations and the cells from which these tumors first start.

16 Feb 2011

Leading foundations support Australian diabetes treatment

Two international charitable foundations, New Zealand-based Cure Kids and U.S.-based Children with Diabetes Foundation, have each pledged to provide US$140,000 to fund the final two patients in a Phase II clinical trial in New Zealand that has the potential to transform the treatment of Type 1 diabetes.

15 Feb 2011

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

Raptor Pharmaceutical Corp., today announced it has reopened enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate in patients with nephropathic cystinosis.

15 Feb 2011

Almac's Director plans to speak on adaptive trial designs at CTS Europe conference

The Almac Group announced today that Graham Nicholls, Director of Biostatistics for Almac's Clinical Technologies business unit, will be speaking at the Clinical Trial Supply Europe conference held in Barcelona, Spain, 22-23 February 2011.

15 Feb 2011

'Real world' guidelines may effectively prevent cardiovascular disease in women

Practical medical advice that works in the "real world" may more effectively prevent cardiovascular disease in women than recommendations based only on findings in clinical research settings, according to the 2011 update to the American Heart Association's cardiovascular disease prevention guidelines for women.

15 Feb 2011

Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint

Oncolytics Biotech Inc. today announced preliminary results from a U.S. Phase 2 clinical trial (REO 017) using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar®) in patients with advanced pancreatic cancer. The trial is being conducted at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio (CTRC).

15 Feb 2011

Study shows lower success rate of FDA drug approval from 2003 to 2010

Biotechnology Industry Organization Industry Analysis and BioMedTracker announced results of a study today that shows the overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2010 is near one in 10. Previous reports, taken from earlier years, showed the rate of drug approvals is one in five to one in six.

15 Feb 2011

Researchers to develop automation system for sedation control in hospital ICUs

Researchers at the Georgia Institute of Technology and the Northeast Georgia Medical Center are one step closer to their goal of automating the management of sedation in hospital intensive care units. They have developed control algorithms that use clinical data to accurately determine a patient's level of sedation and can notify medical staff if there is a change in the level.

14 Feb 2011

U-Systems completes pivotal study for automated breast ultrasound cancer screening

U-Systems, the leader in automated breast ultrasound today announced the completion of a pivotal ROC Reader Study for automated breast ultrasound cancer screening. Conducted by University of Chicago, an acclaimed pioneer in women's heath research, the multi-reader, multi-case (MRMC) ROC Reader Study was carried-out to evaluate the sensitivity of somo•v™ Automated Breast Ultrasound (ABUS) together with a screening mammogram in detecting breast cancer in women with dense breast tissue.

14 Feb 2011

Chimerix announces completion of $45 million Series F financing

Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.

14 Feb 2011

GW plays key role in NIH's Management of Myelomeningocele Study

Researchers at The George Washington University Medical Center played a key role in a National Institutes of Health (NIH) study of a surgical procedure to repair a common birth defect of the spine, which if undertaken while a baby is still in the uterus, greatly reduces the need to divert, or shunt, fluid away from the brain. The study was published online in the New England Journal of Medicine on February 9, 2011.

14 Feb 2011

PROLOR reports positive DSMB review of long-acting human growth hormone clinical trial

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today reported that patient enrollment and dosing in the Phase II trial of its long-acting version of human growth hormone (hGH-CTP) are proceeding according to plan, with study completion targeted for mid-year 2011.

14 Feb 2011

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

AVEO Pharmaceuticals, Inc. today announced that previously reported positive clinical data evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC) will be featured in several poster presentations at the American Society of Clinical Oncology (ASCO) 2011 Genitourinary Cancers Symposium being held February 17-19, 2011 at the Orlando World Center Marriott in Orlando, Fla.

14 Feb 2011

Independent Safety Monitoring Board recommends Vical's Allovectin-7 Phase 3 trial to continue as per protocol

Vical Incorporated today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 trial of Allovectin-7® in patients with metastatic melanoma has completed the trial's fifth scheduled safety analysis and recommended that the trial continue per the protocol.

14 Feb 2011

Clinical Trial News and Research

Patient on artificial heart receives heart and kidney transplant

UT Southwestern treats breast-cancer patient with Accuray CyberKnife System

CTI's fourth quarter net loss increases to $34.1 million

AMT 2010 total net income increases to EUR 1.4 million

Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL

Endosense announces completion of enrollment in EFFICAS I clinical study

Researchers identify cell of origin for sarcoma

Leading foundations support Australian diabetes treatment

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

Almac's Director plans to speak on adaptive trial designs at CTS Europe conference

'Real world' guidelines may effectively prevent cardiovascular disease in women

Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint

Study shows lower success rate of FDA drug approval from 2003 to 2010

Researchers to develop automation system for sedation control in hospital ICUs

U-Systems completes pivotal study for automated breast ultrasound cancer screening

Chimerix announces completion of $45 million Series F financing

GW plays key role in NIH's Management of Myelomeningocele Study

PROLOR reports positive DSMB review of long-acting human growth hormone clinical trial

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

Independent Safety Monitoring Board recommends Vical's Allovectin-7 Phase 3 trial to continue as per protocol

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News